UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Pharmacokinetics and pharmacodynamics of gliteritinib in patients
with relapsed or refractory acute myeloid leukemia.
Authors*: Catherine Choy Smith, Mark J. Levis, Mark Robert Litzow, Alexander E. Perl, Jessica K. Altman,
Stan Gill, Geoffrey Yuen, Peter Bonate, Takeshi Kadokura, Angela Joubert James, Charles Liu, Itsuro Nagase,
Ogert Fisniku, Erkut Bahceci
Abstract #: 7026
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM
Location: Hall A, Poster Board #18
Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant.
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7026)
Smith Research Interests: Our laboratory focuses on identification of therapeutic resistance mechanisms
and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations
in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively
activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ
a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on
the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize
samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how
tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent
these evolutionary adaptations.
http://cancer.ucsf.edu/people/profiles/smith_catherine.3369
*UCSF authors in bold
68